U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H26O5
Molecular Weight 358.4281
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PREDNISONE

SMILES

[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]3([H])[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=XOFYZVNMUHMLCC-ZPOLXVRWSA-N
InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H26O5
Molecular Weight 358.4281
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including

Prednisone is a synthetic anti-inflammatory glucocorticoid derived from cortisone. Prednisone is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions. The pharmacological effects of prednisone which are due to its corticosteroid properties include: promotion of gluconeogenesis; increased deposition of glycogen in the liver; inhibition of the utilization of glucose; anti-insulin activity; increased catabolism of protein; increased lipolysis; stimulation of fat synthesis and storage; increased glomerular filtration rate and resulting increase in urinary excretion of urate (creatinine excretion remains unchanged); and increased calcium excretion. Depressed production of eosinophils and lymphocytes occurs, but erythropoiesis and production of polymorphonuclear leukocytes are stimulated. Inflammatory processes (edema, fibrin deposition, capillary dilatation, migration of leukocytes and phagocytosis) and the later stages of wound healing (capillary proliferation, deposition of collagen, cicatrization) are inhibited. Prednisone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to sodium retention and hypertension. Prednisone is completely converted to the active metabolite prednisolone, which is further metabolized mainly in the liver and excreted in the urine as sulfate and glucuronide conjugates. The exposure of prednisolone is 4-6 fold higher than that of prednisone.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
RAYOS

Approved Use

RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions

Launch Date

1.34326085E12
Palliative
RAYOS

Approved Use

RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions

Launch Date

1.34326085E12
Palliative
RAYOS

Approved Use

RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions

Launch Date

1.34326085E12
Palliative
RAYOS

Approved Use

RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions

Launch Date

1.34326085E12
Palliative
RAYOS

Approved Use

RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions

Launch Date

1.34326085E12
Palliative
RAYOS

Approved Use

RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions

Launch Date

1.34326085E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15.4 μg/L
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PREDNISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
97 μg × h/L
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PREDNISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.85 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PREDNISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
50%
PREDNISONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, adult
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources: Page: p. 92
unhealthy, adult
n = 144
Health Status: unhealthy
Age Group: adult
Population Size: 144
Sources: Page: p. 92
Disc. AE: Vertigo, Abdominal pain upper...
AEs leading to
discontinuation/dose reduction:
Vertigo (1%)
Abdominal pain upper (1%)
Gastroesophageal reflux disease (1%)
Intestinal functional disorder (1%)
Nausea (1%)
Dizziness (1%)
Aphasia (1%)
Headache (1%)
Renal pain (1%)
Sources: Page: p. 92
AEs

AEs

AESignificanceDosePopulation
Abdominal pain upper 1%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources: Page: p. 92
unhealthy, adult
n = 144
Health Status: unhealthy
Age Group: adult
Population Size: 144
Sources: Page: p. 92
Aphasia 1%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources: Page: p. 92
unhealthy, adult
n = 144
Health Status: unhealthy
Age Group: adult
Population Size: 144
Sources: Page: p. 92
Dizziness 1%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources: Page: p. 92
unhealthy, adult
n = 144
Health Status: unhealthy
Age Group: adult
Population Size: 144
Sources: Page: p. 92
Gastroesophageal reflux disease 1%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources: Page: p. 92
unhealthy, adult
n = 144
Health Status: unhealthy
Age Group: adult
Population Size: 144
Sources: Page: p. 92
Headache 1%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources: Page: p. 92
unhealthy, adult
n = 144
Health Status: unhealthy
Age Group: adult
Population Size: 144
Sources: Page: p. 92
Intestinal functional disorder 1%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources: Page: p. 92
unhealthy, adult
n = 144
Health Status: unhealthy
Age Group: adult
Population Size: 144
Sources: Page: p. 92
Nausea 1%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources: Page: p. 92
unhealthy, adult
n = 144
Health Status: unhealthy
Age Group: adult
Population Size: 144
Sources: Page: p. 92
Renal pain 1%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources: Page: p. 92
unhealthy, adult
n = 144
Health Status: unhealthy
Age Group: adult
Population Size: 144
Sources: Page: p. 92
Vertigo 1%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources: Page: p. 92
unhealthy, adult
n = 144
Health Status: unhealthy
Age Group: adult
Population Size: 144
Sources: Page: p. 92
PubMed

PubMed

TitleDatePubMed
Pulmonary mucosa-associated lymphoid tissue lymphoma in a patient with common variable immunodeficiency syndrome.
2001
Bilateral empyema caused by adult-onset Still's disease.
2001
Choroidal granulomas in systemic sarcoidosis.
2001
Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers.
2001
Hodgkin's disease: clinical presentation and treatment.
2001
Validation of liquid-liquid extraction followed by flow-injection negative ion electrospray mass spectrometry assay to Topiramate in human plasma.
2001
The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents.
2001
Current status of cytotoxic chemotherapy in hormone refractory prostate cancer.
2001 Feb
Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease.
2001 Feb
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.
2001 Feb
Hepatic dysfunction as the presenting feature of acute lymphoblastic leukemia.
2001 Feb
Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon.
2001 Feb
The usefulness of quantitative orbital magnetic resonance imaging in Graves' ophthalmopathy.
2001 Feb
Mycophenolic acid plasma concentrations: influence of comedication.
2001 Feb
Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine.
2001 Feb
Prednisone withdrawal followed by interferon alpha for treatment of chronic hepatitis C infection: results of a randomized controlled trial.
2001 Feb
Recalcitrant allergic contact dermatitis from azathioprine tablets.
2001 Feb
Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.
2001 Feb
[Can 67Ga citrate predict the efficacy of chemotherapy early in Hodgkin's lymphoma?].
2001 Feb
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
2001 Feb
Can we induce tolerance in rheumatoid arthritis?
2001 Feb
Idiopathic leukonychia totalis and partialis in a 12-year-old patient.
2001 Feb
Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris.
2001 Feb
Fistulation of the auditory tube diverticulum (guttural pouch) with a neodymium:yttrium-aluminum-garnet laser for treatment of chronic empyema in two horses.
2001 Feb 1
A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.
2001 Feb 13
Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia.
2001 Feb 15
Sample size calculations for the two-sample problem using the multiplicative intensity model.
2001 Feb 28
Remission of precapillary pulmonary hypertension in systemic lupus erythematosus.
2001 Jan
Pyodera gangrenosum after aortic valve replacement.
2001 Jan
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
2001 Jan
Gingival overgrowth as the initial paraneoplastic manifestation of Hodgkin's lymphoma in a child. A case report.
2001 Jan
Lupus-like syndrome with submassive hepatic necrosis associated with hepatitis A.
2001 Jan
Macrohematuria with electron-dense deposits in a 14-year-old boy with minimal change nephrotic syndrome.
2001 Jan
Fatal cytomegalovirus disease in a high-risk renal transplant recipient.
2001 Jan
Nocardia pleural empyema complicating anti-Jo1 positive polymyositis during immunoglobulin and steroid therapy.
2001 Jan
Systemic vasculitis in patients with hepatitis C.
2001 Jan
Factors associated with low bone mineral density in female patients with systemic lupus erythematosus.
2001 Jan
A rationale for adjuvant surgical intervention in pyoderma gangrenosum.
2001 Jan
Effective steroid-sparing treatment for peripheral ulcerative keratitis and pyoderma gangrenosum.
2001 Jan
Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome.
2001 Jan
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
2001 Jan
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
2001 Jan 15
Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.
2001 Jan 16
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
2001 Jan 16
Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection.
2001 Jan 27
Autologous hematopoietic stem-cell transplantation for Behçet's disease with pulmonary involvement.
2001 Jan 4
[Life threatening hypercalcemia in a young man with ALL].
2001 Jan 5
Retinopathy due to juvenile polymyositis.
2001 Jan-Feb
Use of biological markers of airway inflammation to detect the efficacy of nurse-delivered asthma education.
2001 Jan-Feb
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
2001 Mar 1
Patents

Sample Use Guides

The initial dosage of RAYOS (prednisone) may vary from 5 to 60 mg per day depending on the specific disease entity being treated based on relative potency.
Route of Administration: Oral
In Vitro Use Guide
Peripheral blood lymphocytes (PBL) or peripheral CD4(+) and CD8(+) T cell subsets were cultured in the presence of prednisone (PDN) at 10(-3)-10(-12)M concentrations for 72, 96 and 120h. Apoptosis is clearly increased by PDN and the apoptotic effect of PDN is stronger on CD8(+) than on CD4(+) T lymphocytes.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:51:36 UTC 2023
Edited
by admin
on Fri Dec 15 15:51:36 UTC 2023
Record UNII
VB0R961HZT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PREDNISONE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   VANDF   WHO-DD  
INN  
Official Name English
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
Systematic Name English
PREGNA-1,4-DIENE-3,11,20-TRIONE, 17,21-DIHYDROXY-
Systematic Name English
PREDNISONE TABLETS [USP-RS]
Common Name English
PREDNISONE INTENSOL
Brand Name English
Prednisone [WHO-DD]
Common Name English
SUPERCORTIL
Common Name English
METACORTANDRACIN
Common Name English
PREDNISONE [USP MONOGRAPH]
Common Name English
PREDNISONE ANHYDROUS
Common Name English
3EN3HG4WSW
Common Name English
PREDNISONE [GREEN BOOK]
Common Name English
NSC-10023
Code English
prednisone [INN]
Common Name English
DELTASONE
Brand Name English
DEHYDROCORTISONE
Common Name English
PREDNISONE [USP-RS]
Common Name English
PREDNISONE [ORANGE BOOK]
Common Name English
PREDNISONE [EP MONOGRAPH]
Common Name English
PREDNISONE TABLETS
USP-RS  
Common Name English
PREDNISONE [IARC]
Common Name English
PREDNISONE [VANDF]
Common Name English
PREDNISONE [HSDB]
Common Name English
PREDNISONE [MART.]
Common Name English
PREDNISONE [MI]
Common Name English
DECORTIN
Brand Name English
PREDNISOLONE IMPURITY B [EP IMPURITY]
Common Name English
Classification Tree Code System Code
WHO-ATC H02AB07
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
WHO-ATC A07EA03
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
WHO-VATC QH02AB07
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
NCI_THESAURUS C521
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
IARC Prednisone
WHO-VATC QH02AB57
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
CFR 21 CFR 522.1890
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
LIVERTOX 795
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
NDF-RT N0000175450
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
WHO-VATC QA07EA03
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
NDF-RT N0000175576
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C770
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
RXCUI
8640
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY RxNorm
HSDB
3168
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
MERCK INDEX
m9112
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY Merck Index
RS_ITEM_NUM
1559006
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
FDA UNII
VB0R961HZT
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
CHEBI
8382
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
INN
536
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
DRUG BANK
DB00635
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
DRUG CENTRAL
2253
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-160-3
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
IUPHAR
7096
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
EVMPD
SUB10020MIG
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
DAILYMED
VB0R961HZT
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
RS_ITEM_NUM
1559505
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
ALTERNATIVE
SMS_ID
100000091943
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
PUBCHEM
5865
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
MESH
D011241
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
EPA CompTox
DTXSID4021185
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
LACTMED
Prednisone
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
ChEMBL
CHEMBL635
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
NSC
10023
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
CAS
53-03-2
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
WIKIPEDIA
PREDNISONE
Created by admin on Fri Dec 15 15:51:36 UTC 2023 , Edited by admin on Fri Dec 15 15:51:36 UTC 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
MINOR
URINE
METABOLITE -> PARENT
MINOR
URINE
METABOLITE -> PARENT
MINOR
URINE
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
MINOR
URINE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
MAXIMUM TOLERATED DOSE TOXICITY
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC PREDNISOLONE (ACTIVE METABOLITE), ORAL
PHARMACOKINETIC
DELAYED-RELEASE, ORAL
PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC